CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs
approved by the Food and Drug Administration (FDA) for use in the treatment of different
cancers. Their use in this exact combination is considered experimental for the treatment of
pancreas and biliary tract; however the combination has been tested in a preliminary trial.
We are also testing a survey designed. The purpose of this research study is to investigate
the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine
chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients
report their side effects from chemotherapy treatments.